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The cytotoxic death ligand TRAIL (tumor necrosis fac-
tor-related apoptosis-inducing ligand) is a tumor-spe-
cific agent under development as a novel anticancer
therapeutic agent. However, some reports have demon-
strated toxicity of certain TRAIL preparations toward
humanhepatocytesandkeratinocytesthroughacaspase-
dependent mechanism that involves activation of the
extrinsic death pathway and Type II signaling through
the mitochondria. We have isolated and purified both
His-tagged protein and three versions of native recom-
binant human TRAIL protein from Escherichia coli. We
found that 5 mM dithiothreitol in the purification proc-
ess enhanced oligomerization of TRAIL and resulted in
the formation of hyper-oligomerized TRAILs, including
hexamers and nonomers with an extremely high po-
tency in apoptosis induction. Although death-inducing
signaling complex formation was much more efficient in
cells treated with hyper-oligomerized TRAILs, this did
not convert TRAIL-sensitive Type II HCT116 colon tu-
mor cells to a Type I death pattern as judged by their
continued sensitivity to a caspase 9 inhibitor. Moreover,
TRAIL-resistant Type II Bax-null colon carcinoma cells
were not converted to a TRAIL-sensitive Type I state by
hyper-oligomerized TRAIL. Primary human esophageal
epithelial 2 cells were found to be sensitive to all TRAIL
preparations used, including trimer TRAIL. TRAIL-in-
duced death in esophageal epithelial 2 cells was pre-
vented by caspase 9 inhibition for up to 4 h after TRAIL
exposure. This result suggests a possible therapeutic
application of caspase 9 inhibition as a strategy to re-
verse TRAIL toxicity. Hyper-oligomerized TRAIL may
be considered as an alternative agent for testing in clin-
ical trials.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)1 is a Type II transmembrane protein that binds to one
of four receptors that have been identified in humans, includ-
ing TRAIL-R1/DR4 (1), TRAIL-R2/KILLER/DR5 (2–4), TRAIL-
R3/DcR1/TRID (5, 6), and TRAIL-R4/DcR2/TRUNDD (7). Both
DR4 and DR5 are pro-apoptotic receptors, which contain a
cytoplasmic death domain and mediate apoptosis on binding to
TRAIL. By contrast, TRID and TRUNDD do not contain a
cytoplasmic death domain and block the function of TRAIL by
competing with TRAIL-R1 and TRAIL-R2 for binding of
TRAIL (8).
Apoptosis is an essential process for the regulation of home-
ostasis and development. The apoptotic process can be induced
by two different pathways (9). The intrinsic pathway, also
called the mitochondrial pathway, is induced by intracellular
signals such as oncogene activation, DNA-damaging agents,
and growth factor deprivation. Mitochondrial release of cyto-
chrome c into the cytosol in response to death signals allows
assembly of a multiprotein caspase activating complex called
the apoptosome (10, 11). The extrinsic pathway is activated by
cell surface death receptors, and activation of the death recep-
tors by death ligand engagement induces the formation of a
death-inducing signaling complex (DISC), which consists of the
receptor FADD as an adaptor and caspase 8 as an initiator
caspase (12). Once the DISC is formed, the caspase 8 is auto-
processed and activated by induced proximity (13, 14). The
TRAIL death ligand induces apoptosis via the extrinsic path-
way (15).
TRAIL is a promising agent for development as a cancer-
specific therapeutic agent because it induces apoptotic cell
death in a wide variety of transformed cell lines and tumors in
animal models but not in most normal cells or tissues (15–17).
Even in tumor cell lines that show resistance to TRAIL, com-
bined treatment with chemotherapeutic drugs or ionizing ra-
diation has revealed induction of tumor cell death (18–24).
However, some reports have demonstrated a toxicity of certain
TRAIL preparations against primary human hepatocytes
through a caspase-dependent mechanism that involves activa-
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tion of the extrinsic death pathway (25, 26). Further studies
suggested that this toxicity could be avoided by use of native
TRAIL but not tagged TRAIL (27). In this study, we generated
His-tagged and native TRAIL using several biochemical puri-
fication methods. In the case of native TRAIL produced in the
presence of dithiothreitol, we observed and purified hyper-
oligomerized forms that were found to be highly potent in death
induction assays. We investigated the toxicity of the various
recombinant TRAIL preparations toward normal human
esophageal epithelial cells and found evidence of significant
toxicity. We further developed a strategy for using caspase 9
blockade to inhibit toxicity and now report that administration
of a caspase 9 inhibitor is effective for a period of up to 4 h
following TRAIL exposure. Our studies have implications for
the use of TRAIL as an anticancer agent during its utilization
in clinical trials.
EXPERIMENTAL PROCEDURES
Expression Plasmids for Tagged and Untagged Soluble Human
TRAIL—The extracellular portion (aa 95281) of the human TRAIL
cDNA was amplified and cloned into pQE80L (Qiagen) after digestion
with BamHI and HindIII to generate the His6-tagged TRAIL expression
plasmid (pQE-hTR). The primer sequences used were 5-AAGGCGGA-
TCCACCTCTGAGGAAACCATTTC-3 (hTR-S) and 5-CCCAAGCTTT-
TAGCCAACTAAAAAGGCCCCGA-3 (hTR-AS). To make a non-tagged
native human TRAIL expression plasmid, the His6 tag and amino acids
95113 were removed from pQE-hTR by a two-step PCR-mediated
ligation. The first PCR step was performed to amplify the vector and
TRAIL sequences using primers for the vector sequence 5-CGTATCA-
CGAGGCCCTTTCGTC-3 (Head-S) and 5-TTTCTCTCACCATAGTTA-
ATTTCTCCTCTTTAA (Head-AS)-3 and for TRAIL aa 114281, 5-
GAAATTAACTATGGTGAGAGAAAGAGGTCCTCA-3 (TR114) and
5-CCCAAGCTTTTAGCCAACTAAAAAGGCCCCGA-3 (hTR-AS), re-
spectively. Pfu Turbo DNA polymerase was used to prevent 3-nucleo-
tide addition. The amplified products from the first step were mixed and
reamplified with primers Head-S and hTR-AS. The amplified product
was cloned into pQE80L after digestion with EcoRI and HindIII to
generate pQE-nTR.
Purification of Soluble Recombinant Human TRAIL—Recombinant
TRAILs were expressed in DH10B bacteria as the expression host. The
overnight seed culture was diluted 100-fold into 1.0 liter of LB broth
and incubated for 3 h at 37 °C. Isopropyl-1-thio--D-galactopyranoside
(0.5 mM) was added to induce recombinant protein expression, and
bacterial cells were incubated overnight at 30 °C. Bacteria were har-
vested and homogenized in lysis buffer (50 mM sodium phosphate, pH
8.0, 300 mM NaCl, 10 mM imidazole, and 10 mM -mercaptoethanol or 5
mM dithiothreitol). Recombinant TRAILs were isolated from the soluble
fraction using Ni-NTA agarose beads (Qiagen) after washing with lysis
buffer containing 20 mM imidazole. Isolated proteins were dialyzed
against phosphate-buffered saline with 10 mM -mercaptoethanol. The
purity of the recombinant TRAIL proteins was confirmed by SDS-PAGE
and Coomassie Blue gel staining.
Separation of Oligomerized Forms of Soluble Recombinant Human
TRAIL—The recombinant human TRAIL purified from the Ni-NTA-
agarose column application was subjected to gel filtration chromatog-
raphy to isolate oligomerized forms of TRAIL. The HiLoad 60/120
Superdex 200 prep grade column was used in the AKTA fast protein
liquid chromatography system (Amersham Biosciences).
Cell Lines and Culture—Human primary esophageal epithelial cells
(EPC2) were described previously (28). EPC2 cells were cultured in
keratinocyte-SFM (Invitrogen) containing bovine pituitary extract (40
g/ml) and epidermal growth factor (1 ng/ml). Human foreskin fibro-
blasts were described previously (29) and grown in Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum and antibiotics. The
recombinant human soluble DR5 was produced using the Pichia pasto-
ris system as we described previously (30). The purified soluble DR5
contains 1–2 ng of lipopolysaccharide/mg of protein as determined by
Limulus amebocyte lysate assay. This is comparable with human serum
albumin purchased from Sigma, which contains 1–4 ng of lipopolysac-
charide/mg of protein.
Assessment of TRAIL-mediated Apoptosis—For detecting apoptosis
mediated by TRAIL, the active caspase 3 assay was performed using a
Cytofix/Cytoperm kit (BD Biosciences) as described previously (31).
Briefly, 5 105 cells were seeded into a 6-well plate. After 24 h, the cells
were treated with TRAIL. After treatment, the cells were harvested,
fixed, and incubated with 0.125 g/l rabbit anti-active caspase 3
antibody (clone C92-605, Pharmingen) for 20 min. After washing, the
cells were probed with 0.125 g/l phycoerythrin-conjugated goat anti-
rabbit secondary antibody (CALTAG Laboratories) for 20 min. The
intensity of phycoerythrin was analyzed by flow cytometry using a
Beckman Coulter Epics Elite analyzer. For the analysis of the sub-G1
fraction, cells were fixed in 70% ethanol, stained with 50 g/ml pro-
pidium iodide and RNase A for 30 min at room temperature, and then
analyzed by flow cytometry.
DISC Immunoprecipitation—H460 cells (4  107) were harvested
and suspended in 2 ml of Dulbecco’s modified Eagle’s medium with 100
ng/ml trimer or hexamer TRAIL. After incubation with TRAIL prepa-
rations for 5, 10, or 20 min, cells were collected and lysed in 1 ml of
DISC immunoprecipitation buffer (10 mM Tris, pH 7.5, 150 mM NaCl,
10% glycerol, 1 mM EDTA, 1% Triton X-100) with protease inhibitor
mixture. Cell lysates (400 l) were incubated overnight with 5 l of
rabbit anti-FADD antibody (Cell Signaling) at 4 °C. Complexes were
precipitated by protein A-agarose (Invitrogen) and suspended in 50 l of
SDS sample buffer after three washes with DISC immunoprecipitation
buffer. Immunoprecipitates were subjected to SDS-PAGE and Western
blotting.
RESULTS
Generation of Recombinant TRAILs and Their Toxicity
against Human Cancer Cell Lines—hTR, which has an N-
terminal histidine tag, was purified from the DH10B Esche-
richia coli strain after overnight incubation in 0.5 mM isopro-
pyl-1-thio--D-galactopyranoside for protein induction. We
used three different expression and purification schemes for
the generation of native TRAILs (Table I). All TRAILs were
purified using an Ni-NTA-agarose column application, and
TRAIL protein purity was confirmed by SDS-PAGE and Coo-
massie Blue staining (Fig. 1A). Although the native TRAIL
preparations (nTRs) did not contain a His6 tag in their se-
quence, they still bound to the Ni-NTA-agarose column, but the
interaction was relatively weak, allowing separation from the
beads at 40 mM imidazole, whereas the His-tagged hTR re-
quired 250 mM imidazole to be released (data not shown).
The death-inducing activity of each TRAIL was tested in
H460, a human lung adenocarcinoma cell line, which is sensi-
tive to TRAIL. All the purified recombinant TRAIL proteins
could induce apoptosis in H460 cells (Fig. 1B). The hTR and
nTR1 proteins induced less than 15% cell death at 10 ng/ml.
The hTR protein induced more than 40% cell death at 100
ng/ml, whereas nTR1 was only slightly less toxic than hTR,
resulting in 30% cell death at 100 ng/ml. Incubation of TRAIL
proteins in the presence of soluble DR5 protein resulted in a
blockade of apoptosis, thereby confirming the specificity of hTR
and nTR1 for the TRAIL-mediated death receptor pathway. We
also used a decoy receptor-expressing SW480 human colorectal
carcinoma cell line to further confirm the specificity of hTR and
TABLE I
Conditions for generation of recombinant TRAILs
Tag Amino acids residues Growth medium Purification buffer
hTR His6 95–281, 23 kDa LB Phosphate buffer with 10 mM BME
a
nTR1 — 114–281, 19 kDa LB Phosphate buffer with 10 mM BMEa
nTR2 — 114–281, 19 kDa LB Phosphate buffer with 5 mM DTTb
nTR3 — 114–281, 19 kDa LB with 100 M ZnSO4 Phosphate buffer with 5 mM DTT
b
a BME, -mercaptoethanol.
b DTT, dithiothreitol.
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nTR1 for TRAIL receptor-mediated apoptosis (Fig. 1, C and D).
We introduced a cytosolic death domain-deleted mouse KILL-
ER/DR5 gene, which was fused with GFP into the SW480 cells
(SWMK), and found that this artificial decoy receptor could
protect from cell death induced by hTR or nTR1. The death-
inducing activity of hTR was comparable with that of commer-
cially available preparations (32, 33). Interestingly, the death-
inducing activity of nTR2 and nTR3 appeared to be higher than
that observed with nTR1, although all three were expressed
from the same expression plasmid and host. Death induction
following exposure to nTR2 and nTR3 resulted in a cell death
rate greater than 40%, even at 10 ng/ml TRAILs, and death
occurred rapidly by 1 h after treatment with higher doses of
TRAIL. This hyperactivity of nTR2 and nTR3 was mediated
specifically by the cell surface TRAIL death receptors because
soluble DR5 protein almost completely blocked their cytotoxic-
ity. These results suggested that nTR2 and nTR3 were some-
how different from hTR and nTR1, although they were com-
posed of a homogeneous TRAIL component. These results
prompted us to examine the multimeric state of the TRAIL
molecules.
Hyper-oligomerization Correlates with High Cytotoxicity of
nTR2 and nTR3—Gel filtration chromatography revealed that,
depending on the method of purification, TRAIL molecules
were heterogeneous in their oligomeric state (Fig. 2). In the
case of hTR, one peak corresponding to the trimer was ob-
served, whereas nTR1 appeared to be a mixture of monomer,
dimer, and trimer molecules. The existence of an N-terminal
His tag appeared to facilitate the trimerization of TRAIL mol-
ecules. Surprisingly, nTR2 and nTR3, which were purified in a
5 mM DTT-containing buffer, appeared to consist of timer,
hexamer, and a small amount of nonomer. Each peak corre-
sponding to a trimer, hexamer, or nonomer was composed of
TRAIL molecules as verified by reducing SDS-PAGE. There
was no apparent difference in the molecular composition of
nTR2 versus nTR3, which suggested that the addition of zinc
ions in the culture medium did not influence the oligomeriza-
tion state of TRAIL molecules. However, there was a highly
significant difference in the molecular conformation in nTR1
versus nTR2, although the same procedure was used in the
overexpression and purification of the TRAIL molecules, except
that the reducing agent was changed from 10 mM -mercapto-
ethanol to 5 mM DTT. The use of DTT during purification
greatly enhanced the oligomerization of native TRAIL mole-
cules, which resulted in the formation of hexamers and nono-
mers. DTT also led to the disappearance of monomers and
dimers observed with nTR1.
We next investigated the apoptosis-inducing capacity of var-
ious TRAIL preparations and found that hexamers and nono-
mers were the highly cytotoxic component of nTR2 and nTR3.
Hexamer and nonomer TRAIL proteins could kill the majority
of H460 cells within 1 h of treatment at 100 ng/ml, and no cells
survived after 4 h of treatment. In contrast, trimer TRAIL
Procedures.” The purity of the purified recombinant TRAIL proteins
was checked by SDS-PAGE and Coomassie Blue staining of the protein
gel. B, the cytotoxicity of each TRAIL preparation was investigated in
H460 cells. Each TRAIL preparation was added for 4 h, and cells were
harvested and stained for the active form of caspase 3 and analyzed by
fluorescence-activated cell sorter. nTR2 and nTR3 showed high potency
in inducing apoptosis. C, SW480 cells expressing either GFP (SWGFP)
or the cytosolic domain-truncated mouse KILLER/DR5-GFP fusion pro-
tein (SWMK) were subjected to the treatment by the indicated concen-
tration of TRAIL proteins for 4 h, and apoptosis was checked by the
active caspase 3 assay. D, bright field (left panels) and fluorescent (right
panels) microscopic images of SWGFP and SWMK. The decoy receptor
expression was identified as the membrane expression of GFP fusion
protein.
FIG. 1. Generation of recombinant TRAILs and their cytotox-
icity. A, each TRAIL preparation was purified using a Ni-NTA-agarose
column after overnight induction as described under “Experimental
Death Induction by Recombinant Native TRAIL40046
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exposure resulted in more modest cell killing under the same
conditions. Cell death induced by hyper-oligomerized TRAIL
proteins was blocked by the soluble DR5 protein (Fig. 3A). We
also checked the cleavage of caspases following TRAIL expo-
sure. Trimer TRAIL treatment resulted in cleavage of pro-
caspases 8, 9, and 3, but significant amounts of pro-caspases
remained after 4 h of treatment. In the case of hexamer TRAIL,
we observed cleavage of most of the cellular caspases 8 and 3
within 1 h, accompanied by complete disappearance of the
pro-form of caspases 8 and 3 within 2 h. Significant amounts of
pro-caspase 9 remained at 1 h but disappeared by 2 h on
treatment with hexamer TRAIL. The extent of cleavage of the
caspases was proportional to the potency of the TRAILs
(Fig. 3B).
Hyper-oligomerized TRAIL Induced More Efficient DISC
Formation—Because hexamer TRAIL induced apoptosis more
efficiently than trimer TRAIL, we wondered whether DISC
formation was more efficient following binding of hexamer
versus trimer TRAIL. We performed DISC immunoprecipita-
tion using anti-FADD antibody to examine the recruitment and
cleavage of DISC components following exposure of H460 cells
to either trimer or hexamer TRAIL. Using 100 ng/ml trimer or
hexamer TRAIL, we observed a time-dependent increase in the
recruitment and cleavage of caspase 8 and c-FLIP to the DISC
(Fig. 3C). We also observed increased recruitment of DR4 to the
DISC. This increase was much greater in hexamer TRAIL-
treated cells showing a significantly greater amount of recruit-
ment and cleavage even at a 5-min exposure, which was com-
parable with the amount observed following 20 min of exposure
to the trimer TRAIL. We also investigated whether the more
efficient DISC formation and death induction by hexamer
TRAIL might influence whether cell death occurred by a Type
I versus a Type II mechanism. To determine whether cell death
became less sensitive to inhibition by the caspase 9 inhibitor
LEHD-fluoromethyl ketone (34), we treated either H460 (Type
I) or HCT116 (Type II) cells with trimer or hexamer TRAIL and
examined cell death induction at 6 h (Fig. 4A). H460 cells
showed marginal death protection by the caspase 9 inhibitor
(C9I) treatment, whereas complete death protection was con-
ferred by the caspase 8 inhibitor (C8I), consistent with a Type
I cell death protection pattern. There was no difference in the
degree of observed death protection by the caspase inhibitors
whether trimer or hexamer TRAIL was used to treat the H460
cells. In HCT116 cells, the C9I completely blocked cell death
induced by either trimer or hexamer TRAIL. Despite more
efficient formation of DISC by hexamer TRAIL, this did not
alleviate the need to amplify the death signal through mito-
chondrial activation of caspase 9 as occurs in the Type II cell
death pattern. We further confirmed these observations by
examining the sub-G1 fraction and colony viability (Fig. 4, B
and C, respectively) of Bax-null HCT116 cells, which are
TRAIL-resistant because the Bax deficiency prevents their
death by a Type II mechanism (33, 35). Bax-null cells remained
resistant regardless of the oligomeric state of TRAIL used.
Native TRAIL, Including Trimer TRAIL, Induced Death of
Human Primary Esophageal Epithelial Cells—TRAIL is be-
lieved to selectively induce cell death of tumor cells but not
most normal cells. We tested our TRAIL preparations for po-
tential cytotoxic effects toward normal human cell lines. Hu-
man foreskin fibroblasts appeared completely refractory to
TRAIL-induced death regardless of the method of TRAIL prep-
aration (Fig. 5A). In contrast, EPC2 cells displayed significant
sensitivity to the various TRAIL preparations (Fig. 5B). We
recently demonstrated that these cells are sensitive to His-
tagged recombinant TRAIL (36). We treated the EPC2 cells
with 50 ng/ml of each TRAIL preparation and, using the active
caspase 3 fluorescence-activated cell sorter assay, found that
EPC2 were sensitive to all four TRAIL preparations (Fig. 5B);
however, the hyper-oligomerized TRAIL preparations were
clearly more toxic toward the EPC2 cells.
There have been some reports that His-tagged or leucine
zipper TRAIL preparations induced cell death in human pri-
mary keratinocytes or hepatocytes (25, 27, 37). There was also
a report that optimally trimerized soluble TRAIL did not in-
duce apoptosis in human hepatocytes (27). When we compared
the dose dependence of cell death induced by trimer TRAIL in
EPC2 and H460 cells, EPC2 cells showed a sensitivity to
TRAIL similar to that of the H460 lung cancer cells (Fig. 5C),
although our trimer TRAIL has optimally trimerized conforma-
tion according to our gel filtration results (Fig. 2).
TRAIL-induced Cell Death in Human Primary Esophageal
Epithelial Cells Was Prevented by Treatment with a Caspase 9
Inhibitor Even after Initiation of Apoptosis—We previously re-
ported that human primary hepatocytes were sensitive to His-
tagged TRAIL treatment, but this death was prevented by
co-treatment with the C9I (34). We also showed that the C9I
could not prevent apoptosis induced by TRAIL in H460 and
SW480 cell lines because these tumor cell lines were killed by
FIG. 2. Hyper-oligomerization of TRAIL was observed in nTR2
and nTR3. The oligomeric state of TRAIL proteins was analyzed by gel
filtration chromatography. The hTR was composed of trimer TRAIL and
showed one peak corresponding to 65 kDa. nTR1 gel filtration showed
a mixture of three forms, which consist of monomer, dimer, and trimer.
Trimer, hexamer, and nonomer forms of TRAIL were identified in nTR2
and nTR3. Each peak in nTR3 was collected and subjected to SDS-
PAGE for the verification of the TRAIL molecule. Gel filtration samples
for hTR, nTR1, and nTR2 were run at a flow rate of 1.0 ml/min, but
nTR3 was run at 0.5 ml/min velocity, which resulted in sharper peaks
and a good separation between the hexamer and the nonomer peaks. x
axis represents the elution volume.
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a Type I mechanism that was not sensitive to blockade of
caspase 9 activated by the mitochondrial signaling pathway. In
the present study, we evaluated the death-protective effect of
C9I especially after the death signal had been initiated by
TRAIL. First, we added the C9I or the soluble DR5 protein at
0-, 1-, 2-, 4-, and 6-h time points during a 6-h culture of EPC2
cells exposed to 100 ng/ml trimer TRAIL at time 0 (Fig. 6A). At
the zero time point, when each of the death blockers, C9I or
soluble DR5, was added with trimer TRAIL, the death was
prevented completely. At the 1-h time point, in the case when
the death blockers were added at 1 h after trimer TRAIL, the
C9I prevented the death completely, whereas the soluble DR5
only protected by 50% from death induced by the 6-h treat-
ment using trimer TRAIL. Even at the 2-h time point, we found
a potent protective effect of the C9I. Remarkably, the death-
protective effect of C9I addition could still be demonstrated as
a 50% protection from cell death even after 4 h of trimer TRAIL
exposure, whereas soluble DR5 showed no protection from
death induced by the total 6-h treatment of trimer TRAIL
(when the inhibitors were added similarly at 4 h). Next, we
extended the cell culture time with trimer TRAIL to 24 h and
investigated whether this death protection was transient (Fig.
6B). These results confirmed that even if EPC2 cells were
exposed for 24 h to trimer TRAIL, the addition of C9I at 4 h
after TRAIL exposure resulted in 50% protection from cell
death, observed at 24 h.
We also tested the death-protective effect of C9I on death
induced by hexamer TRAIL, which induced a more potent and
rapid apoptosis than that observed with trimer TRAIL. As
shown in Fig. 6C, we observed more than 50% cell death pro-
tection by C9I at the 2-h time point when 2 or 5 ng/ml hexamer
TRAIL was used. The dose that showed similar death inducing
activity was 100 ng/ml for trimer TRAIL, whereas 10 or 20
ng/ml hexamer TRAIL induced massive apoptosis such that
less than 50% cell death protection was observed at the 2-h
time point of C9I treatment. Next, we checked whether using
the 2-h time point for caspase 9 blockade could rescue the death
of HCT116, which shows a Type II cell death pattern, and
found significant death protection by the 2-h time point C9I
treatment in either hexamer and trimer TRAIL-treated cells
(Fig. 6D).
DISCUSSION
In the present studies, we generated several forms of native
TRAIL as well as His-tagged TRAIL and examined their tox-
icity toward human cancer cell lines and human primary cells.
We found that native TRAIL could adopt different oligomeric
states depending on the purification conditions, particularly in
regard to the use of DTT during purification. Moreover, the
cytotoxicity of various TRAIL preparations varied greatly, and
this appeared to correlate with their oligomeric state.
Soluble TRAIL was identified as a stable trimer, which con-
tains a zinc ion in the x-ray structural analysis (38). We found
that addition of 5 mM DTT during purification significantly
increased the oligomerization of TRAIL, which resulted in
higher order molecules, including hexamers and a small
amount of nonomers in addition to trimer TRAIL. We observed
no difference in the oligomeric composition of nTR2 (purified
with DTT without additional zinc) versus nTR3 (purified withFIG. 3. Hyper-oligomerization of TRAIL correlated with the
high potency of nTR2 and nTR3 in cytotoxicity assays. A, H460
cells were subjected to treatment with 100 ng of each TRAIL prepara-
tion/ml for 4 h, and cell death was checked by phase-contrast micros-
copy examination. Hyper-oligomerized TRAIL preparations (hexamer
and nonomer) induced total cell death, and their activity was blocked by
1.5 g/ml soluble DR5 protein treatment. B, H460 cells were exposed to
100 ng of each TRAIL preparation/ml and harvested for the Western
blot at the indicated time points. Cleavage of caspases and death
substrates was proportional to the activity of the TRAIL preparations.
C, DISC immunoprecipitation of H460 cells was carried out at 5, 10, or
20 min with 100 ng of TRAIL trimer or hexamer/ml and analyzed for
recruitment of caspase 8, DR4, and c-FLIP. Immunoprecipitation was
performed using 5 l of polyclonal anti-FADD antibody (Cell Signaling)
and protein A-agarose for 24 h. Immunoblotting was performed for
caspase 8 (mouse monoclonal, clone 3-1-9, BD Biosciences), DR4 (goat
polyclonal, R&D Systems), c-FLIP (mouse monoclonal, clone NF6,
Alexis), and FADD (mouse monoclonal, BD Biosciences).
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DTT plus additional zinc), and there was no difference in their
oligomeric profile as seen in Fig. 2. This suggests that addi-
tional ZnSO4 in the LB medium did not influence the oligo-
meric state of TRAIL molecules. According to Lawrence et al.
(27) and Hymowitz et al. (38), the zinc ion concentration in the
culture medium may have an effect on the proper oligomeriza-
tion of the TRAIL molecule. These studies used M9 minimal
medium for the culture of E. coli, which is reported to contain
trace metal ions, whereas we used LB medium, which may
contain metal ions. This is possibly one reason for the lack of
observed differences in the activity and conformation of our
nTR2 and nTR3 preparations.
Hyper-oligomerized hexamer and nonomer TRAIL showed a
much higher cytotoxicity compared with trimer TRAIL and
FIG. 4. Type II cell death mechanism was not changed by highly potent hexamer TRAIL. A, H460 cells were exposed to trimer (100
ng/ml) or hexamer (10 ng/ml) TRAIL for 6 h. 50 M caspase 8 or 9 inhibitor was added at the same time with TRAIL. Cell death was measured
by propidium iodide staining and sub-G1 fraction. In the case of HCT116, which is much more sensitive to TRAIL, 20 ng/ml trimer or 2 ng/ml
hexamer TRAIL was used. B, dose-dependent cell death was measured in HCT116 wild-type (WT) and Bax-null cells. Cell death was checked at
the 6- and 24-h time points. C, death-inducing activity of each TRAIL preparation was compared using HCT116 wild-type and Bax-null cells. The
upper plate contains wild-type HCT116 cells, whereas the lower plate contains Bax-null HCT116 cells. The final dose of TRAIL preparations (ng/ml)
used is indicated in the grid. 1  105 cells were plated in each well, cells were exposed to TRAIL for 48 h, and then plates were stained with
Coomassie Blue.
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induced more rapid apoptosis. This hyperactivity might be
explained by the facilitation of receptor clustering that was
found in a Fas-signaling pathway (39). Hyper-oligomerized
TRAIL could potentially aggregate more than three receptor
molecules, thereby inducing rapid receptor clustering, which
results in rapid and strong intracellular signal transmission.
We found that hexamer TRAIL was more efficient at recruit-
ment of the DISC components (Fig. 3C) but was not capable of
promoting death of Type II cells in the presence of caspase 9
blockade (Fig. 4, A and B). Treatment with hyper-oligomerized
TRAIL also did not result in killing of TRAIL-resistant Bax-
null HCT116 cells (Fig. 4C) that die by a Type II mechanism in
response to TRAIL. This is in contrast to the effect of the
combination of TRAIL plus CPT11 that we recently showed
was capable of killing the Bax-null HCT116 cells through an
apparent conversion to the Type I mechanism, which in this
FIG. 5. Sensitivity of primary human cells to TRAIL. A, human foreskin fibroblasts were tested for sensitivity to TRAIL and appeared totally
refractory to all TRAIL preparations used, up to 1 g/ml. Cell survival was checked by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay after 24 h of treatment with TRAIL. B, EPC2 cells were exposed to 100 ng/ml TRAIL preparations with or without soluble DR5 receptor for 4 h,
and cell death was measured by staining for the active form of caspase 3 and analysis by flow cytometry. Although this is a normal cell line, significant
death was induced by all TRAIL preparations used. The percentage of active caspase 3-positive cells is shown for treatment with only TRAIL (left
panels) and TRAIL with soluble DR5 receptor cells (right panels). C, EPC2 and H460 cells were exposed to trimer TRAIL at the indicated concentrations
(ng/ml) for 4 h. Sensitivity to trimer TRAIL of EPC2 cells was almost the same as that of H460 lung cancer cells.
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case involved, at least in part, p53-dependent up-regulation of
KILLER/DR5 (35). Thus, hyper-oligomerized TRAIL does not
promote Type I-mediated killing of Type II cells.
Recombinant human soluble TRAIL is a candidate tumori-
cidal agent, which can induce apoptosis in a variety of human
cancer cell lines but not in normal cells. Although some cancer
cell lines are not sensitive, TRAIL could induce apoptosis in
resistant cell lines when combined with chemotherapeutic
drugs, ionizing radiation, or cytokines (18–24). It has been
shown that TRAIL could induce apoptosis in several animal
tumor xenograft models (16, 17). One potential obstacle for
clinical trials lies in the fact that TRAIL might be toxic to
certain human cells, especially hepatocytes because His-tagged
TRAIL induced a strong apoptotic response in cultured human
primary hepatocytes (25). Some studies, however, have sug-
gested that native TRAIL (unlike tagged TRAIL) was less toxic
toward normal hepatocytes and keratinocytes in culture. There
has been no published explanation as to why tagged TRAIL
acts differently than native TRAIL only with respect to killing
of normal human primary cells because both TRAIL prepara-
tions presumably use the same signaling pathway, and their
effect can be blocked by a caspase-9 inhibitor (34).
The toxicity of TRAIL to human primary cells could repre-
sent a hindrance to the use of TRAIL to treat cancer patients.
In this study, we demonstrated that human primary esopha-
geal epithelial cells were sensitive to trimer and hyper-oli-
gomerized TRAIL preparations. Importantly, we showed that
this toxicity could be avoided by caspase 9 inhibitor treatment.
We evaluated the death-protective effect of C9I or soluble DR5.
The soluble DR5 protein treatment represents the clearing of
TRAIL molecules in the culture environment and could not
block the death pathway already initiated by TRAIL prior to
FIG. 6. Toxicity of TRAIL toward EPC2 cells could be reversed by use of a caspase 9 inhibitor treatment even after initiation of
TRAIL-induced cell death. A, the 6-h time point for the protection from death by death inhibitors (caspase 9 inhibitor (filled bars) and soluble
DR5 (open bars)) is shown. During 6 h of culture of EPC2 cells with 100 ng/ml trimer TRAIL, C9I or soluble DR5 was added to the medium at the
indicated time points. At 6 h, cells were harvested for the active caspase 3 assay. B, the 24-h time point experiment for the protection from death
by death blockers. All conditions were the same as in B except the EPC2 cell culture time with trimer TRAIL, which was continued for 24 h. C,
EPC2 cells were exposed to hexamer TRAIL for 6 h, and death protection by caspase 9 inhibitor was measured at 0- (open bars) and 2-h (hatched
bars) time points. Filled bars, no C9I. D, HCT116, which shows Type II cell death, was exposed to hexamer or trimer TRAIL for 6 h, and death
prevention by caspase 9 inhibitor was measured at 0- (open bars) and 2-h (hatched bars) time points. Filled bars, no C9I.
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clearance of the TRAIL. On the other hand, C9I showed an
excellent death-protective effect, and nearly no cell death was
noticed even when administered 2 h after trimer TRAIL expo-
sure. Furthermore, C9I prevented nearly 50% of cell death at
4 h of trimer TRAIL exposure, and this was observed even with
a 24-h total duration of trimer TRAIL exposure. We believe this
is a significant finding that provides a safety window for the
monitoring of TRAIL toxicity, which might occur during clinical
use of recombinant human TRAIL. After administration of
TRAIL, any sign of cell death in major organs in 2–4 h may
possibly be reversed by caspase 9 inhibitor treatment. Al-
though it was not as strong as trimer TRAIL-treated cells, the
C9I treatment showed significant cell death protection when
EPC2 cells were exposed to hexamer TRAILs. The hyper-oli-
gomerized TRAIL preparations, which show high potency and
also high toxicity to EPC2 cells, could be considered a thera-
peutic agent for tumor-specific therapy.
In conclusion, we generated several recombinant soluble
TRAIL preparations and found that the oligomerization status
of TRAIL determines the potency of TRAIL in killing cells. We
also found that human primary esophageal epithelial cells are
sensitive to various TRAIL preparations and that the death
induced by TRAIL could be reversed by caspase 9 inhibitor
treatment even after the death-signaling pathway was initi-
ated. The death protection by caspase 9 inhibitor treatment is
a specific phenomenon to the cells with the Type II cell death
mechanism. This is not unique to normal cell lines because we
could observe similar death protection by caspase 9 inhibition
in the HCT116 human colon cancer cell line. But fortunately,
many tumor cells acquire mesenchymal characteristics during
tumor progression and tend to die by a Type I pathway,
whereas normal epithelial cells tend to die by a Type II mech-
anism. This phenomenon has been recently demonstrated for
Fas signaling (40). This evolution during tumor progression
may provide an Achilles’ heel for many tumor cells that may be
sensitive to Type I TRAIL-mediated cell death (not inhibitable
by caspase 9 blockade), although normal epithelial cells can be
protected. The protective effect of the caspase 9 inhibitor may
be useful in the clinic in combination with recombinant TRAIL.
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